Develops and sells medicines for rare disorders, including treatments for metabolic and neurological diseases, for children and adults.
10-K for FY2025, filed Feb 19, 2026
Partners pay upfront license fees, milestone payments and royalties on future product sales; the company also earns fees for research and development services. Medicine customers are generally invoiced after delivery, though some countries pay in advance.
10-K for FY2025, filed Feb 19, 2026The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license…View ↗
For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from…View ↗
The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD…View ↗
$1.7B
10-K for FY2025, filed Feb 19, 2026
$1.7B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
34%
FY2022: 77%
|
Net product revenue, FY2025
$586.7M Sources
|
Sold outright |
|
Collaboration and license revenue
Licensed
10-K for FY2025, filed Feb 19, 2026 |
58% |
Collaboration and license revenue, FY2025
$998.4M Sources
|
Licensed |
|
Royalty revenue
Licensed
10-K for FY2025, filed Feb 19, 2026 |
14%
FY2022: 16%
|
Royalty revenue, FY2025
$244.2M Sources
|
Licensed |
|
Manufacturing revenue
|
0.0%
FY2022: 0.0%
|
Manufacturing revenue, FY2025
$0 Sources
|
Medicine orders come from distributors, hospitals, specialty pharmacies and retail pharmacies; pharmaceutical collaborators license programs and may fund research and development.
10-K for FY2025, filed Feb 19, 2026
Yes. It kept 39 cents of every revenue dollar as net income in FY2025 and turned 41 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
−$51.7MView ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Aug 28, 2026
On August 25, 2026, PTC Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Asset Purchase Agreement”) with…View ↗
8-K, filed Jul 30, 2026
– Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950…View ↗
Growing. Revenue grew 3.2x in 4 years, from $538.6M in FY2021 to $1.7B in FY2025, about 34% a year.
Sephience's status
Sephience advanced from a clinical-stage PKU candidate to an approved product for children and adults.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 19, 2026Metabolic Platform – The most advanced molecule in our metabolic platform is sepiapterin. We initiated a registration-directed Phase 3…View ↗
In June 2025, Sephience was granted marketing authorization by the EC for the treatment of children and adults living with PKU within the…View ↗
Translarna's EEA authorization
Translarna had marketing authorization in the EEA for nmDMD; the latest report says the European Commission adopted a decision not to renew it, while individual EU countries may allow continued use.
10-K for FY2022, filed Feb 21, 2023 10-K for FY2025, filed Feb 19, 2026Global DMD Franchise – We have two products, TranslarnaTM (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular…View ↗
We previously had a marketing authorization for Translarna in the EEA, which had been subject to annual review and renewal by the EC…View ↗
Competes with Otsuka Pharmaceutical, SOM Biotech, Maze Therapeutics, Agios Pharmaceuticals, Santhera Pharmaceuticals, Sarepta Therapeutics, NS Pharma, Dyne Therapeutics, Wave Life Sciences, Daiichi Sankyo, Nippon Shinyaku, Solid Biosciences, REGENXBIO, Alnylam Pharmaceuticals, Pfizer, BridgeBio Pharma, Intellia Therapeutics, Biogen, Novartis, and uniQure
10-K for FY2025, filed Feb 19, 2026Sephience for PKU. Sephience faces competition from Kuvan (sapropterin dihydrochloride), including generic versions, and Palynziq…View ↗
Loading...